Latest Headlines

Latest Headlines

Readers' picks, responses to Fierce's 'Top 10' cancer drugs report

I've tried to capture some of the most interesting responses we've gotten over the past few days since we published our 2012 report.

Celldex brain cancer vaccine increases survival in Phase II

Celldex Therapeutics ($CLDX) has unveiled overall survival data from a 65-person Phase II trial of the company's brain cancer vaccine rindopepimut. In the single-arm trial, the Needham, MA-based

Celldex stock hit hard, but cancer vaccine shows promise

Biotech stocks were rocked last week when Dendreon, which makes the only approved cancer vaccine, reported that sales of Provenge significantly missed their mark. Dendreon lost two-thirds of its